NASDAQ : AGEN
Agenus Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 6.84 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 307.94M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 307.94M |
| Enterprise Value | 329.91M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 45.02M |
| Shares Outstanding | 45.02M |
| Shares Change (YoY) | +51.00% |
| Shares Change (QoQ) | +7.97% |
| Owned by Insiders (%) | 1.48% |
| Owned by Institutions (%) | 40.02% |
| Float | 40.23M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 2.73 |
| Forward PE | n/a |
| PS Ratio | 2.32 |
| Forward PS | 3.32 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 3.59 |
| EV / Sales | 2.49 |
| EV / EBITDA | 8.12 |
| EV / EBIT | 9.19 |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.34 |
| Quick Ratio | 0.32 |
| Debt / Equity | n/a |
| Debt / EBITDA | 0.81 |
| Debt / FCF | n/a |
| Interest Coverage | 0.60 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | 12.53% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -60.69% |
| Weighted Average Cost of Capital (WACC) | 24.62% |
| Revenue Per Employee | $1.64M |
| Profits Per Employee | $1.13M |
| Employee Count | 81 |
| Asset Turnover | 0.74 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.52 |
| 52-Week Price Change | +77.66% |
| 50-Day Moving Average | 7.59 |
| 200-Day Moving Average | 4.93 |
| Relative Strength Index (RSI) | 46.72 |
| Average Volume (20 Days) | 841,718 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 7.00M |
| Short Previous Month | 6.82M |
| Short % of Shares Out | 15.55% |
| Short % of Float | 17.41% |
| Short Ratio (days to cover) | 6.16 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 132.69M |
| Gross Profit | 150.75M |
| Operating Income | 35.88M |
| Pretax Income | 91.94M |
| Net Income | 91.80M |
| EBITDA | 40.61M |
| EBIT | 35.88M |
| Earnings Per Share (EPS) | $2.51 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 18.74M |
| Total Debt | 40.71M |
| Net Cash | -21.97M |
| Net Cash Per Share | -$0.49 |
| Equity (Book Value) | -205.85M |
| Book Value Per Share | -4.67 |
| Working Capital | -153.01M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -98.50M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 4.73M |
| Net Borrowing | -2.14M |
| Free Cash Flow | -98.50M |
| FCF Per Share | -$2.19 |
Margins
| Measure | Value |
|---|
| Gross Margin | 113.61% |
| Operating Margin | 27.04% |
| Pretax Margin | 69.29% |
| Profit Margin | 69.34% |
| EBITDA Margin | 30.60% |
| EBIT Margin | 27.04% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -51.00% |
| Shareholder Yield | n/a |
| Earnings Yield | 36.63% |
| FCF Yield | -31.99% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $26.33 |
| Price Target Difference | 284.94% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 4.17% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Apr 12, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -16.78 |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |